Table 3.
The genotype and allele distribution and odds ratios (OR) of the g.1289209T>C and c.73G>A polymorphisms of the UBC9 gene for triple negative breast cancer patients
| Genotype or allele | Triple negative (n = 24) | Others (n = 142) | OR | OR (95 % Cl) | P value |
|---|---|---|---|---|---|
| g.1289209T>C | |||||
| C/C | 8 | 72 | 1.00 ref. | ||
| C/T | 11 | 60 | 1.07 | 0.43–2.63 | 0.886 |
| T/T | 5 | 10 | 4.13 | 1.21–14.1 | 0.024 |
| C | 27 | 204 | 1.00 ref. | ||
| T | 21 | 80 | 2.09 | 1.07–4.08 | 0.030 |
| c.73G>A | |||||
| GG | 8 | 40 | 1.00 ref. | ||
| GA | 11 | 71 | 0.89 | 0.37–2.17 | 0.796 |
| AA | 5 | 31 | 0.96 | 0.33–2.85 | 0.944 |
| G | 27 | 151 | 1.00 ref. | ||
| A | 21 | 133 | 0.92 | 0.49–1.72 | 0.793 |
Triple negative–ER, PR and HER2 negative breast cancer patients
Others–at last one receptor positive breast cancer patients (ER or PR or HER2 positive)